You are here:
Information Letter on Zeposia (Ozanimod): Modified dosing recommendation for mild or moderate chronic hepatic impairment (Child-Pugh class A or B)
2023.08.18
Active substance: ozanimod
Bristol Myers Squibb, in coordination with the German Federal Institute for Drugs and Medical Devices (BfArM), informs about the recommendation for dose reduction in patients with mild or moderate chronic hepatic impairment (Child-Pugh class A or B) due to the risk of overdose. The training material (checklist for physicians) has been updated accordingly and has been sent to healthcare professionals together with this information letter.
Available in German only:
Download DHPC / Information letter , Download_VeroeffentlichtAm_EN